Ursodeoxycholic acid and liver disease associated with cystic fibrosis: A multicenter cohort study
- 1 April 2021
- journal article
- research article
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 21 (2), 220-226
- https://doi.org/10.1016/j.jcf.2021.03.014
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsyJournal of Hepatology, 2010
- Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progressionJournal of Hepatology, 2010
- High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitisJournal of Hepatology, 2009
- Epidemiology of liver disease in cystic fibrosis: a longitudinal studyJournal of Hepatology, 2004
- Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcomeJournal of Hepatology, 2002
- Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcomeJournal of Hepatology, 2002
- The diagnosis of cystic fibrosis: A consensus statementThe Journal of Pediatrics, 1998
- A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver diseaseJournal of Hepatology, 1998
- Liver function and morphology during long‐term fatty acid supplementation in cystic fibrosisLiver International, 1994
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988